Key Articles and Guidelines in the Management of Pulmonary Arterial Hypertension: 2011 Update

被引:2
|
作者
Johnson, Samuel G. [1 ]
Kayser, Steven R. [2 ]
Attridge, Rebecca L. [3 ,4 ]
Duvall, Laura [7 ]
Kiser, Tyree H. [6 ]
Moote, Rebecca [8 ]
Reed, Brent N. [5 ]
Rodgers, Jo E. [9 ]
Erstad, Brian [10 ]
机构
[1] Univ Colorado Skaggs Sch Pharm & Pharmaceut S, Clin Pharm Serv, Kaiser Permanente Colorado, Aurora, CO USA
[2] Univ Calif San Francisco, Sch Pharm, Dept Clin Pharm, San Francisco, CA 94143 USA
[3] Univ Texas Hlth Sci Ctr San Antonio, Univ Incarnate Word Feik Sch Pharm, San Antonio, TX 78229 USA
[4] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Dis & Crit Care Med, San Antonio, TX 78229 USA
[5] Univ N Carolina Hlth Care, Chapel Hill, NC USA
[6] Univ Colorado Skaggs Sch Pharm & Pharmaceut Sci, Dept Clin Pharm, Aurora, CO USA
[7] Ohio State Univ Med Ctr, Dept Pharm, Columbus, OH USA
[8] Regis Univ, Dept Pharm Practice, Sch Pharm, Rueckert Hartman Coll Hlth Profess, Denver, CO USA
[9] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC USA
[10] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA
来源
PHARMACOTHERAPY | 2012年 / 32卷 / 06期
关键词
pulmonary arterial hypertension; right heart failure; drug therapy; guidelines;
D O I
10.1002/j.1875-9114.2012.01105.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pharmacotherapeutic approaches for the management of pulmonary arterial hypertension (PAH) have expanded greatly in the last 10 years. Pulmonary arterial hypertension is a relatively rare disease and is associated with myriad disease processes. The older term for PAH, primary PAH, has been changed to represent these differences and to distinguish it from postcapillary PAH associated with left-sided heart failure. Limitations in evaluating treatment approaches for PAH include its rarity, the small number of patients included in clinical trials, and issues regarding the use of placebo-controlled trials in a disease with such a high mortality rate if left untreated. Management options include the use of prostacyclin and prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase inhibitors, as well as traditional background therapy with diuretics, digoxin, calcium channel blockers, and warfarin. Numerous drugs are under investigation to evaluate their possible roles in management. Combination therapy is increasingly becoming a standard approach to therapy, with mounting literature to document effectiveness. Current or emerging roles for the pharmacist in the management of PAH largely involves ensuring access to drug therapy, facilitating specialty pharmacy dispensing, and providing patient counseling. Newer roles may include future drug development, optimized use of investigational drugs, and specialized disease management programs. This compilation includes a series of articles identifying important literature in cardiovascular pharmacotherapy. This bibliography focuses on pharmacotherapeutic management of pulmonary arterial hypertension (PAH). Most of the cited works present the results of significant human clinical studies that have shaped the management of patients with PAH. Limited primary literature is available for some topics, so in addition, consensus documents prepared by expert panels are reviewed. This compilation may serve as a teaching tool, reference resource, or update of the literature for pharmacy clinicians, physicians, and students.
引用
收藏
页码:e134 / e169
页数:36
相关论文
共 50 条
  • [1] Key Articles and Guidelines in the Management of Hypertension: 2008 update
    Gaffney, Sarah M.
    de Denus, Simon
    Olson, Kari L.
    Ripley, Toni L.
    Robinette, Bryan
    Summers, Kelly M.
    Spencer, Anne P.
    PHARMACOTHERAPY, 2008, 28 (08): : 1041 - 1058
  • [2] Request to "Update" the 2019 Update of Guidelines for Management of Pulmonary Arterial Hypertension
    Durrani, Jameel
    Toor, Amit
    CHEST, 2019, 156 (01) : 187 - 187
  • [3] Key articles and guidelines in the management of hypertension
    de Denus, S
    Hardy, AM
    Olson, KL
    Robinette, B
    PHARMACOTHERAPY, 2004, 24 (10): : 1385 - 1399
  • [4] Key Articles and Guidelines in the Management of Dyslipidemia: 2019 Update
    Wiggins, Barbara S.
    Dixon, Dave
    Bellone, Jessica
    Gasbarro, Nicole
    Marrs, Joel C.
    Tran, Rebecca
    JOURNAL OF PHARMACY PRACTICE, 2020, 33 (06) : 882 - 894
  • [5] Key Articles and Guidelines in the Management of Peripheral Arterial Disease
    Stacy, Zachary A.
    Dobesh, Paul P.
    Trujillo, Toby C.
    Dager, William E.
    Ripley, Toni
    Olson, Kari L.
    PHARMACOTHERAPY, 2011, 31 (09): : 922 - 922
  • [6] Key Articles and Guidelines in the Management of Heart Failure: 2018 Update
    Jackevicius, Cynthia A.
    Page, Robert L.
    Buckley, Leo F.
    Jennings, Douglas L.
    Nappi, Jean M.
    Smith, Andrew J.
    JOURNAL OF PHARMACY PRACTICE, 2019, 32 (01) : 77 - 92
  • [7] Update on Medical Management of Pulmonary Arterial Hypertension
    Sherman, Alexander E.
    Saggar, Rajan
    Channick, Richard N.
    CARDIOLOGY CLINICS, 2022, 40 (01) : 13 - 27
  • [8] Selexipag in the management of pulmonary arterial hypertension: an update
    Coghlan, J. Gerry
    Picken, Christina
    Clapp, Lucie H.
    DRUG HEALTHCARE AND PATIENT SAFETY, 2019, 11 : 55 - 64
  • [9] Key articles and guidelines for the emergency medicine clinical pharmacist: 2011-2018 update
    Acquisto, Nicole M.
    Slocum, Giles W.
    Bilhimer, Matthew H.
    Awad, Nadia, I
    Justice, Stephanie Baker
    Kelly, Gregory F.
    Makhoul, Therese
    Patanwala, Asad E.
    Peksa, Gary D.
    Porter, Blake
    Truoccolo, Donna M. Shuler
    Treu, Cierra N.
    Weant, Kyle A.
    Thomas, Michael C.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2020, 77 (16) : 1284 - 1335
  • [10] New Guidelines on Management of Arterial Hypertension: Key Similarities and Differences
    Kobalava, Zhanna D.
    Troitskaya, Elena A.
    Kolesnik, Eteri L.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2019, 15 (01) : 105 - 114